More recently, the international phase III SOLO2 study evaluated olaparib as maintenance therapy in platinum-sensitive, relapsed ovarian cancer patients with a BRCA1/2 mutation treated with at least two lines of previous chemotherapy [16]. This evidence concerns the gene BRCA1 and ovarian carcinoma.